Discover
MTVA
MetaVia Inc.
1.45
2 x 1.06
2 x 1.84
bid
ask
+
0.02
1.40%
2 @ 05:48 AM
1.47 +0.02 (1.10%)
| Ytd | -82.78% | |
| 1y | -79.72% |
1.42
day range
1.49
0.97
52 week range
19.03
| Open | 1.42 | Prev Close | 1.43 | Low | 1.42 | High | 1.49 | Mkt Cap | 7.49M |
| Vol | 65.65K | Avg Vol | 3.77M | EPS | -4.21 | P/E | N/A | Forward P/E | N/A |
| Beta | -0.28 | Short Ratio | 0.65 | Inst. Own | 12.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.85 | 200-d Avg | 5.15 | 1yr Est | 17.33 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-11 | DONG-A ST CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | 5.35M | Sale |
| 2024-06-06 | GLICKMAN MARK A | Director | 9.74K | Stock Award(Grant) |
| 2024-06-06 | GROVES JASON L | Director | 17.55K | Stock Award(Grant) |
| 2023-08-10 | KIM HYUNG HEON | Chief Executive Officer | 625.06K | Stock Award(Grant) |
| 2023-07-26 | KIM NA YEON | Director and Beneficial Owner of more than 10% of a Class of Security | 302.01K | Stock Award(Grant) |
| 2024-06-06 | KOVEN ANDREW IAN | Director | 17.55K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Armistice Capital, LLC | 848.00K | 1.38M | 9.84% |
| 2024-09-29 | Affinity Asset Advisors, Llc | 89.22K | 145.43K | 1.04% |
| 2024-09-29 | Vanguard Group Inc | 60.45K | 98.54K | 0.70% |
| 2024-09-29 | Geode Capital Management, LLC | 32.57K | 53.10K | 0.38% |
| 2024-09-29 | Ferguson Wellman Capital Management, Inc. | 15.67K | 25.54K | 0.18% |
| 2024-09-29 | State Street Corporation | 15.63K | 25.48K | 0.18% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 32.43K | 52.86K | 0.38% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 28.02K | 45.67K | 0.33% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 19.57K | 31.90K | 0.23% |
| 2024-10-30 | Fidelity Total Market Index Fund | 4.75K | 7.74K | 0.06% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 4.75K | 7.74K | 0.06% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 4.67K | 7.61K | 0.05% |